Navigating Prostate Cancer Progression: Risk Assessment and Management

A brief review of the evolving realm of prostate cancer care centered on the significance of identifying high-risk cases and addressing the complexities of risk stratification and prognosis.

EP: 1.Optimizing Prostate Cancer Care: A Collaborative Approach

EP: 2.Choosing Partners in Cancer Care: A Strategic Approach

EP: 3.Early-Stage Prostate Cancer Screening and Management Trends

Now Viewing

EP: 4.Navigating Prostate Cancer Progression: Risk Assessment and Management

EP: 5.Prostate Cancer Hormone Therapies: A Comprehensive Overview

EP: 6.Enhancing Efficacy in Advanced Hormone-Sensitive Prostate Cancer Treatment

EP: 7.Advanced Prostate Cancer: Enhancing Combination Therapy

EP: 8.Overcoming Barriers to Triplet Therapy in Prostate Cancer

EP: 9.Advanced Prostate Cancer: Patient Care Continuity

EP: 10.Optimizing Care Collaboration in Advanced Prostate Cancer

Related Videos

Related Content

Advertisement

March 22nd 2025

Data reinforce isodose MHFRT as standard of care radiotherapy regimen

Hannah Clarke

“These findings reinforce isodose MHFRT as the standard of care, offering the same cancer control as conventional treatment but with fewer side effects than dose-escalated MHFRT,” says Amar U. Kishan, MD.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

March 20th 2025

Trial launches of CBP/p300 inhibitor in mCRPC

Hannah Clarke

Pocenbrodib is an oral, small molecule designed to inhibit the proteins CREBBP/EP300, which activate genes that promote cancer cell growth and proliferation.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

March 17th 2025

Michael R. Folkert, MD, PhD, discusses real-world outcomes with spacer in prostate cancer

Michael R. Folkert, MD, PhD Benjamin P. Saylor

"4 years following radiation therapy, there is a 25% lower hazard of bowel disorders and a 46% lower hazard of related procedures [in patients who received a spacer],” says Michael R. Folkert, MD, PhD.

March 13th 2025

Radioligand therapy shows promising safety in patients with mCRPC

Hannah Clarke

The mean absorbed radiation dose to tumors was 8.9 Gy/GBq, compared with 0.27 Gy/GBq in the kidneys and 0.13 Gy/GBq in the salivary glands.

Related Content

Advertisement

March 22nd 2025

Data reinforce isodose MHFRT as standard of care radiotherapy regimen

Hannah Clarke

“These findings reinforce isodose MHFRT as the standard of care, offering the same cancer control as conventional treatment but with fewer side effects than dose-escalated MHFRT,” says Amar U. Kishan, MD.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

March 20th 2025

Trial launches of CBP/p300 inhibitor in mCRPC

Hannah Clarke

Pocenbrodib is an oral, small molecule designed to inhibit the proteins CREBBP/EP300, which activate genes that promote cancer cell growth and proliferation.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

March 17th 2025

Michael R. Folkert, MD, PhD, discusses real-world outcomes with spacer in prostate cancer

Michael R. Folkert, MD, PhD Benjamin P. Saylor

"4 years following radiation therapy, there is a 25% lower hazard of bowel disorders and a 46% lower hazard of related procedures [in patients who received a spacer],” says Michael R. Folkert, MD, PhD.

March 13th 2025

Radioligand therapy shows promising safety in patients with mCRPC

Hannah Clarke

The mean absorbed radiation dose to tumors was 8.9 Gy/GBq, compared with 0.27 Gy/GBq in the kidneys and 0.13 Gy/GBq in the salivary glands.